Gelonghui, March 28 | Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that the company adheres to product development and introduction strategies with technological innovation as the lead, market demand as the guide, and clinical application value as the core, and continuously optimizes product iterations. In recent years, while ensuring stable performance, the company has rapidly raised the level of R&D investment, improved pipeline layout in multiple fields, actively expanded technical coverage, promoted global layout, promoted technological upgrading and process optimization of existing products, continuously enhanced multi-level R&D pipelines and rich project reserves, and strengthened the construction of innovative technology platforms. In the field of drug research and development, we have built multiple R&D innovation technology platforms, including long-term controlled release technology platforms for protein drugs, ADC drug technology platforms, ultrasound and hydrogel technology platforms, and also combined AI technology to cover all aspects of innovative drug design, screening, evaluation, process development and formulation; continue to promote innovative development strategies in the vaccine field, and dig deeper into the “large-scale virus culture technology platform”, “formulation and adjuvant technology platform”, “genetic engineering technology platform”, and “bacterial vaccine technology platform”, and “bacterial vaccine technology platform”, and signed foreign investment agreements with Communication Biotech. Achieve complementary advantages, accelerate the construction of an “mRNA vaccine technology platform”, form five core technology platforms, effectively promote the development and layout of various mRNA vaccines, and promote the company's diversification of technology and products.